AstraZeneca: rejects 'mini-bid' by TRC Capital

(CercleFinance.com) - AstraZeneca on Monday recommended that its shareholders reject a mini-bid for its American Depositary Shares (ADS) by TRC Capital, a Canadian investment firm that specialises in such transactions.


In a statement, the biopharmaceutical company said that it had been notified of a mini-tender offer by TRC Capital to purchase two million ADSs, or 0.06% of its share capital, at a price of 57.88 dollars per share.

AstraZeneca claims that TRC Capital's offer is approximately 4.5% below the closing price on 8 October, the day before the offer.

As a result, AstraZeneca says it does not endorse this "unsolicited" offer and asks its shareholders to ignore it.


Copyright (c) 2021 CercleFinance.com. All rights reserved.